-
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
28 Jan 2025 00:55 GMT
… without targeted therapy for metastatic breast cancer. Alternatively, they could have … chemotherapy, which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel (Abraxane … low or HER2-ultralow metastatic breast cancer following disease progression after …
-
Tucatinib in Combination With Trastuzumab Demonstrates Safety, Efficacy in Patients With HER2-Mutated Breast Cancer
27 Jan 2025 15:42 GMT
… (HER2)-mutated metastatic breast cancer (MBC).
Mutations in … in combination with capecitabine (Xeloda; Cheplapharm Arzneimittel GmbH) … in HER2-mutated metastatic breast cancer: a phase 2 … patients with advanced HER2+ breast cancer (HER2CLIMB). Updated August …
-
Fulvestrant Yields No OS Differences Vs Anastrozole in HR+ Breast Cancer
23 Jan 2025 23:48 GMT
… [ESR1-mutated advanced breast cancer] that has progressed following … postmenopausal with histologically confirmed breast cancer, positive HR status … 5%), and capecitabine (Xeloda; 11.3% vs 14 … subset of patients with breast cancer. (FALCON). ClinicalTrials.gov …
-
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer
15 Jan 2025 17:58 GMT
Metronomic capecitabine (Xeloda; Genetech) plus an aromatase inhibitor … promising option for patients with breast cancer through improved clinical efficacy and … Administration approval overview in metastatic breast cancer. J Clin Oncol. March 19 …
-
Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer
20 Dec 2024 23:12 GMT
… patients with triple-negative breast cancer (TNBC), circulating tumor … subset having HR–positive breast cancer (12 patients).
Among … .8%) and prior therapy Xeloda, (capecitabine) 13.5%). … triple-negative breast cancer or HER2-, BRCA-mutated breast cancer with …
-
Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset
16 Dec 2024 18:20 GMT
… Center and Key Laboratory of Breast Cancer, Shanghai Medical College, Fudan … SOC per clinical practice guidelines. Xeloda (capecitabine) was allowed in this … or locally advanced triple-negative breast cancer (CamRelief): a randomized, double-blind …
-
The Evolution of ADCs in Breast Cancer: Challenges and Innovations
12 Dec 2024 08:02 GMT
… breast cancer (BC). At the 2024 San Antonio Breast Cancer … ; Novartis) plus capecitabine (Xeloda; Genentech) (9.6 … advanced or metastatic breast cancer (EMILIA). ClinicalTrials.gov … (HER3) positive metastatic breast cancer. ClinicalTrials.gov Identifier: …
-
Enhertu Improves Progression-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Cancer
12 Dec 2024 01:13 GMT
… #47;-ultralow metastatic breast cancer experienced improvements to progression … receptor-positive metastatic breast cancer with HER2-low … patients), which consisted of Xeloda (capecitabine; 59.8%), … at: San Antonio Breast Cancer Conference; December 10- …
-
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
11 Dec 2024 19:52 GMT
… hormone receptor–positive metastatic breast cancer with HER2-low ( … which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel … Presented at: San Antonio Breast Cancer Conference; December 10-13 … or HER2-ultralow metastatic breast cancer (mBC) with prior …
-
T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer
01 Oct 2024 20:48 GMT
… HER2-ultralow advanced or metastatic breast cancer. Investigators presented updated findings … receptor–positive, HER2-negative breast cancer,” lead study author Giuseppe … comparator arm consisted of capecitabine (Xeloda), nab-paclitaxel, or paclitaxel. …
About
© 1995-2025